Proactive Investors - Run By Investors For Investors

Ted Baker upgraded to 'buy' by HSBC following better-than-expected Christmas sales

HSBC said there has been no "discernible impact" on brand performance or reputation following reports of sexual harassment claims against boss Ray Kelvin
Ted Baker
Goldman Sachs, on the other hand, has downgraded its rating to 'neutral'

A better-than-expected Christmas trading update from Ted Baker PLC (LON:TED) has prompted HSBC to upgrade its recommendation on the stock to ‘buy’ from ‘hold’ and raise its target price to 2,215p from 1,450p.

The fashion retailer on Wednesday reported a 10.5% increase in retail sales at constant currency for the five weeks to January 5, compared to consensus expectations of 6% growth for the fourth quarter following a 2.1% rise in the third quarter.

READ: Ted Baker shares jump as fashion retailer unveils solid Christmas sales

“While this update needs to be considered in the right context, i.e. this is a short trading period (five weeks to 5 January) and coincides with a rebound in UK consumer demand, it also underpins the resilience of Ted Baker’s brand appeal during peak trading,” HSBC said.

HSBC added that there appears to be "no discernible impact" on brand performance or reputation following reports of sexual harassment claims against chief executive and founder, Ray Kelvin.  Kelvin has taken a voluntary leave of absence while the allegations are investigated by law firm Herbert Smith Freehills.

However, the bank cut its estimates for pre-tax profit in fiscal years 2019 to 2021 by 4-8% to reflect challenging UK trading conditions.

Shares in Ted Baker fell 6.8% to 1,975p in mid-morning trading.

Meanwhile, Goldman Sachs has taken a different view on Ted Baker, downgrading the stock to ‘neutral’. 

View full TED profile View Profile

Ted Baker Timeline

Related Articles

May 23 2019
Company is looking for more acquisitions after integration of Metro Rod
May 21 2019
"The group's performance over the past three years demonstrates the continuing success of our strategy to access more customers and markets," said chief executive John Nichols.
medical imaging graphic
Here we take a closer look at the imaging and diagnostics firm IQ-AI

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use